Hosted on MSN

10x Genomics’s (NASDAQ:TXG) Q3: Strong Sales, Stock Jumps 13.1%

Biotech company 10x Genomics (NASDAQ:TXG) reported Q3 CY2025 results , but sales fell by 1.7% year on year to $149 million. On top of that, next quarter’s revenue guidance ($156 million at the ...
Nasdaq

Where 10x Genomics Stands With Analysts

Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on 10x Genomics (NASDAQ:TXG) in the last three months. The following table summarizes their recent ...
Benzinga.com

These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results

10x Genomics, Inc. (NASDAQ:TXG) reported a loss for the third quarter on Tuesday. The company posted a quarterly loss of 30 cents per share, compared to market expectations for a loss of 34 cents per ...
La Grande Observer

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ — At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, ...
Nasdaq

10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease

Study aims to identify single cell immune signatures of disease activity and treatment response to support clinical care Autoimmune diseases remain among the most challenging conditions to diagnose ...